Misplaced Pages

Chiglitazar

Article snapshot taken from[REDACTED] with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Chemical compound

Pharmaceutical compound
Chiglitazar
Clinical data
Trade namesBilessglu
Other namesCarfloglitazar
Legal status
Legal status
  • Rx in China
Identifiers
IUPAC name
  • (2S)-3--2-propanoic acid
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC36H29FN2O4
Molar mass572.636 g·mol
3D model (JSmol)
SMILES
  • C1=CC=C2C(=C1)C3=CC=CC=C3N2CCOC4=CC=C(C=C4)C(C(=O)O)NC5=CC=CC=C5C(=O)C6=CC=C(C=C6)F
InChI
  • InChI=1S/C36H29FN2O4/c37-26-17-15-25(16-18-26)35(40)30-9-1-4-10-31(30)38-32(36(41)42)23-24-13-19-27(20-14-24)43-22-21-39-33-11-5-2-7-28(33)29-8-3-6-12-34(29)39/h1-20,32,38H,21-23H2,(H,41,42)/t32-/m0/s1
  • Key:QNLWMPLUWMWDMQ-YTTGMZPUSA-N

Chiglitazar (trade name Bilessglu) is a drug for the treatment of type 2 diabetes. It is a peroxisome proliferator-activated receptor (PPAR) agonist.

In China, chiglitazar is approved for glycemic control in adult patients with type 2 diabetes when used in combination with diet and exercise.

References

  1. Ji L, Song W, Fang H, Li W, Geng J, Wang Y, et al. (August 2021). "Efficacy and safety of chiglitazar, a novel peroxisome proliferator-activated receptor pan-agonist, in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, phase 3 trial (CMAP)". Science Bulletin. 66 (15): 1571–1580. Bibcode:2021SciBu..66.1571J. doi:10.1016/j.scib.2021.03.019. PMID 36654286. S2CID 233650336.
  2. Deeks ED (January 2022). "Chiglitazar: First Approval". Drugs. 82 (1): 87–92. doi:10.1007/s40265-021-01648-1. PMID 34846697. S2CID 244716275.
Stub icon

This pharmacology-related article is a stub. You can help Misplaced Pages by expanding it.

Categories:
Chiglitazar Add topic